 |
Find Data about a New Drug Using the Drug Name?
TOPIC: There are many ways to monitor new drugs in development. You can use the therapeutic class (Find data about new drugs in development by therapeutic class), by a specific phase of development (Find a drug in a specific phase of development anywhere in the world) and by drug name. Two drug pipeline databases: Adis R&D Insight (File 107) and IMS R&D Focus (File 445) contain unique information about a drug. For example, File 107 has a commercial summary of expected sales produced by Lehman Brothers, and File 445 contains product profile records and newsletter entries.
In this example, you will use the drug name Solulin, a drug for treating stroke, currently in clinical trials to find more data about the drug.
COMMAND SUMMARY
BEGIN 445
SELECT SOLULIN/NA
SELECT S1/PROFILE
TYPE S2/9/1
HOW TO...
1. BEGIN File 445, a database containing information about drugs in the pipeline.
2. SELECT the drug name (/NA) and limit to the drug profile (/profile).
|
?B 445
File 445:IMS R&D Focus 1991-2006/Aug W2
(c) 2006 IMS Health & Affiliates
Set Items Description
--- ----- -----------
?SELECT SOLULIN/NA
S1 3 SOLULIN/NA
?SELECT S1/PROFILE
S2 1 S1/PROFILE |
3. TYPE the complete record using Format 9.
The Profile record contains brand name, company and licensing information, drug data including therapeutic class code and clinical indications. |
?T S2/9/1
2/9/1
DIALOG(R)File 445:IMS R&D Focus
(c) 2006 IMS Health & Affiliates. All rts. reserv.
02018513
Brand Name: SOLULIN
R&D Focus - November 07, 2005 (20051107)
COMPANY INFORMATION:
Originator: Schering AG; (Germany); NA; licensor;NA Licensee/Licensor: PAION; (Germany); NA; licensee; NA
Patent Assignee: Schering AG
Licensing Countries: Worldwide
COMPANY INFORMATION:
Licensing Contact: Alexander Vos, Chief Operating Officer,
PAION, Martinstrasse 10-12, 52062 Aachen,Germany
Tel: +49 241 44 53 115; Fax: +49 241 44 53 504;
Email: a.vos@paion.de
DRUG INFORMATION:
CAS Registry Number: 186148-59-4
Pharmacological Action: biotechnology; peptide
Substance Origin: recombinant/biotechnology
Therapeutic Class Code: N7X (All Other CNS Drugs)
Clinical Indications: stroke; trauma; thrombosis
Chemical Name: unspecified
Molecular Code: 9020210000 |
The latest information about the drug is listed, as well as the current development phase and country. |
LATEST INFORMATION:
7 November 2005: Alexander Vos, Chief Operating Officer at PAION, informed R&D focus during an interview at the 13th Annual BioPartnering Europe, 9-11 October 2005, London, UK, that PAION is seeking licensing partners, worldwide, to further develop SOLULIN. SOLULIN, originally developed by Schering AG, is a recombinant peptide version of the membrane
protein thrombomodulin under investigation for the potential treatment of stroke. Preclinical studies of SOLULIN as an antithrombotic and neuroprotective agent are under way in Germany and a phase I safety trial is expected to commence before the end of 2005. SOLULIN, the rights to which were acquired by PAION from Schering AG in March 2002, may also have
potential for the treatment of acute neuronal damage.
CURRENT DEVELOPMENT STATUS:
Highest Phase: Preclinical (20)
Development Phase/
Country/Indication: Preclinical--Germany
DEVELOPMENT HISTORY:
OCT 2005: Available for partnering, Worldwide.
MAR 2002: Preclinical, Germany. Licensing agreement between Schering AG and PAION.
APR 1990: Priority product patent application filed in USA by Schering AG.
|
| A commercial summary including estimates of sales |
COMMERCIAL SUMMARY:
PAION is developing SOLULIN, Schering AG's recombinant peptide version of the membrane protein thrombomodulin, as a treatment for stroke, acute neuronal damage such as spinal cord injury, and thrombosis. Preclinical studies in animal models evaluating the agent as an antithrombotic and neuroprotective agent, are under way in Germany. Schering AG filed a priority product patent application in the USA during April 1990. In March 2002, PAION licensed worldwide rights to SOLULIN from Schering AG. Preclinical studies in animal models evaluating SOLULIN as an antithrombotic
and neuroprotective agent, are under way in Germany (PAION,
MAR 2002). A phase I safety trial of SOLULIN is expected to commence before the end of 2005 (PAION, OCT 2005). Phase I trials were expected to begin second half 2005 (PAION, MAY 2005). Phase I trials were expected to start by end 2003.
PAION has licensed worldwide rights to SOLULIN from Schering
AG (PAION, MAR 2002). Availability Licensing partners for SOLULIN are sought worldwide by PAION (PAION, OCT 2005). A phase I safety trial of SOLULIN is expected to commence before the end of 2005 (PAION, OCT 2005). Phase I trials are
expected to begin second half 2005 (PAION, MAY 2005). Phase I trials were expected to start by end 2003. Latest prediction
Analyst, First Berlin, reporting on PAION, estimates peak sales for SOLULIN of EUR156 million as a treatment for stroke and other thrombotic diseases (First Berlin, JUL 2005). >
|
| A patent summary lists the patent number, publication date and claim. |
PATENT SUMMARY:
US 5256770 1993, priority US 506325 1990, claims a thrombomodulin analog peptide having the native methionine at position 388 replaced with leucine.
|
RELATED HOW DO I...? SOLUTIONS
NEED HELP?
Contact the Dialog Knowledge Center
Within North America 1 800 3 DIALOG (334 2564)
Outside North America 00 800 33 DIALOG (33 34 2564)
Web Form www.dialog.com/contacts/webform
|
You are viewing the
Click below to view the
 |
